Influence of statin therapy on type 2 endoleak evolution

Area of Science:

• Vascular Surgery
• Cardiovascular Research
• Medical Interventions

Background:

• Endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms (AAA) is common but can be complicated by type 2 endoleaks (T2E).
• While T2Es often resolve spontaneously, their progression is unpredictable.
• Statins have demonstrated pleiotropic effects, including potential thrombus stabilization, but their impact on T2E remains unstudied.

Purpose of the Study:

• To investigate the potential influence of statin therapy on the evolution of type 2 endoleaks (T2E) following EVAR.
• To assess whether statins affect T2E persistence, regression, and associated aortic sac changes.

Main Methods:

• Retrospective analysis of 85 patients with T2E after EVAR between 2008-2013.
• Patients were categorized into statin and no-statin groups, with follow-up using duplex ultrasound and CT angiography.
• Primary endpoint: T2E persistence at 6 months and long-term; secondary endpoints: sac shrinkage, growth rate, and reintervention rates.

Main Results:

• Statin users showed a trend towards lower T2E persistence at 6 months (81% vs. 93%) and significantly lower persistence at 36 months (11% vs. 64%, P=0.001).
• Statin therapy was independently associated with T2E regression (HR 0.40, P=0.01).
• Statin patients exhibited higher sac shrinkage rates (18% vs. 3%, P=0.03) and diameter reduction (11 mm vs. 6 mm, P=0.05) at 6 months.

Conclusions:

• Statin therapy appears to promote T2E regression and aortic sac stabilization in the early to medium term after EVAR.
• These findings suggest a potential role for statins in managing T2E complications.
• Prospective studies are required to validate these preliminary results and confirm the clinical impact of statins on T2E outcomes.